



(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 71

(48) Corrigendum issued on:
30.08.2023 Bulletin 2023/35

(43) Date of publication:
25.01.2023 Bulletin 2023/04

(21) Application number: **22190665.4**

(22) Date of filing: **31.08.2011**

(51) International Patent Classification (IPC):
A61K 9/127 (2006.01) **A61K 39/00** (2006.01)
A61P 31/04 (2006.01) **A61P 31/10** (2006.01)
A61P 31/12 (2006.01) **A61P 33/00** (2006.01)
A61P 37/04 (2006.01) **C12N 15/88** (2006.01)
A61K 9/00 (2006.01)

(52) Cooperative Patent Classification (CPC):
A61K 9/127; A61K 9/0019; A61K 9/1271;
A61K 9/1272; A61K 39/00; A61P 31/04;
A61P 31/10; A61P 31/12; A61P 33/00;
A61P 37/04; C12N 15/88; A61K 9/1277;
A61K 2039/53; A61K 2039/55555;
C12N 2710/16134;

(Cont.)

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **31.08.2010 US 37883110 P**

(60) Divisional application:
23179893.5 / 4 233 841

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
21208092.3 / 4 008 357
11755497.2 / 2 611 467

(71) Applicant: **GlaxoSmithKline Biologicals SA**
1330 Rixensart (BE)

(72) Inventors:
• **GEALL, Andrew**
Emeryville, CA 94662-8097 (US)
• **VERMA, Ayush**
Emeryville, CA 94662-8097 (US)

(74) Representative: **West, Heloise**
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS (GB)


Remarks:

This application was filed on 16.08.2022 as a divisional application to the application mentioned under INID code 62.

(54) **SMALL LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA**

(57) Nucleic acid immunisation is achieved by delivering RNA encapsulated within a liposome. The RNA encodes an immunogen of interest, and the liposome has a diameter in the range of 60-180nm, and ideally in the range 80-160nm. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer has a diameter in the range of 60-180nm; and (ii) the aqueous core includes a RNA which encodes an immunogen. These liposomes are suitable for *in vivo* delivery of the RNA to a vertebrate cell and so they are useful as components in pharmaceutical compositions for immunising subjects against various diseases.

FIG. 1



(52) Cooperative Patent Classification (CPC): (Cont.)
C12N 2760/18534; C12N 2770/36143;
C12N 2770/36171